ARTICLE | Clinical News
RFS 2000: Expanded Phase III trial
May 10, 1999 7:00 AM UTC
SuperGen Inc. (SUPG), San Ramon, Calif. Product: RFS 2000 Business: Cancer Therapeutic category: Cell proliferation Target: Topoisomerase I Description: Oral 9-nitrocamptothecin topoisomerase I inhi...